Cargando…
CRISPR/Cas13: A potential therapeutic option of COVID-19
The novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be considered as the most important current global issue, as it has caused the novel coronavirus disease (COVID-19) pandemic, which has resulted in high mortality and morbidity rates all around the world. A...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Masson SAS.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498250/ https://www.ncbi.nlm.nih.gov/pubmed/33152914 http://dx.doi.org/10.1016/j.biopha.2020.110738 |
_version_ | 1783583469636419584 |
---|---|
author | Lotfi, Melika Rezaei, Nima |
author_facet | Lotfi, Melika Rezaei, Nima |
author_sort | Lotfi, Melika |
collection | PubMed |
description | The novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be considered as the most important current global issue, as it has caused the novel coronavirus disease (COVID-19) pandemic, which has resulted in high mortality and morbidity rates all around the world. Although scientists are trying to discover novel therapies and develop and evaluate various previous treatments, at the time of writing this paper, there was no definite therapy and vaccine for COVID-19. So, as COVID-19 has called ideas for treatment, controlling, and diagnosis, we discussed the application of Clustered Regularly Interspaced Short Palindromic Repeats/Cas13 (CRISPR/Cas13) as a treatment of COVID-19, which received less attention compared with other potential therapeutic options. |
format | Online Article Text |
id | pubmed-7498250 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Authors. Published by Elsevier Masson SAS. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74982502020-09-18 CRISPR/Cas13: A potential therapeutic option of COVID-19 Lotfi, Melika Rezaei, Nima Biomed Pharmacother Review The novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be considered as the most important current global issue, as it has caused the novel coronavirus disease (COVID-19) pandemic, which has resulted in high mortality and morbidity rates all around the world. Although scientists are trying to discover novel therapies and develop and evaluate various previous treatments, at the time of writing this paper, there was no definite therapy and vaccine for COVID-19. So, as COVID-19 has called ideas for treatment, controlling, and diagnosis, we discussed the application of Clustered Regularly Interspaced Short Palindromic Repeats/Cas13 (CRISPR/Cas13) as a treatment of COVID-19, which received less attention compared with other potential therapeutic options. The Authors. Published by Elsevier Masson SAS. 2020-11 2020-09-17 /pmc/articles/PMC7498250/ /pubmed/33152914 http://dx.doi.org/10.1016/j.biopha.2020.110738 Text en © 2020 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Lotfi, Melika Rezaei, Nima CRISPR/Cas13: A potential therapeutic option of COVID-19 |
title | CRISPR/Cas13: A potential therapeutic option of COVID-19 |
title_full | CRISPR/Cas13: A potential therapeutic option of COVID-19 |
title_fullStr | CRISPR/Cas13: A potential therapeutic option of COVID-19 |
title_full_unstemmed | CRISPR/Cas13: A potential therapeutic option of COVID-19 |
title_short | CRISPR/Cas13: A potential therapeutic option of COVID-19 |
title_sort | crispr/cas13: a potential therapeutic option of covid-19 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498250/ https://www.ncbi.nlm.nih.gov/pubmed/33152914 http://dx.doi.org/10.1016/j.biopha.2020.110738 |
work_keys_str_mv | AT lotfimelika crisprcas13apotentialtherapeuticoptionofcovid19 AT rezaeinima crisprcas13apotentialtherapeuticoptionofcovid19 |